ELISA/assay

Human Hyaluronan Mediated Motility Receptor ELISA Kit

MBS733934

48-Strip-Wells

470 USD

ELISA Kit

Human Hyaluronan Mediated Motility Receptor ELISA Kit

Hyaluronan Mediated Motility Receptor

hyaluronan mediated motility receptor isoform c; Hyaluronan mediated motility receptor; hyaluronan mediated motility receptor; receptor for hyaluronan-mediated motility; intracellular hyaluronic acid-binding protein; hyaluronan-mediated motility receptor (RHAMM); Intracellular hyaluronic acid-binding protein; Receptor for hyaluronan-mediated motility; CD_antigen: CD168

HMMR/CD168

HMMR; HMMR; CD168; IHABP; RHAMM; IHABP; RHAMM

HMMR_HUMAN

Human

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.

For samples: Serum, plasma, cell culture supernatants, body fluid and tissue homogenate . INTENDED USE This HMMR/CD168 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human HMMR/CD168. This ELISA kit for research use only, not for therapeutic or diagnostic applications! . PRINCIPLE OF THE ASSAY HMMR/CD168 ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-HMMR/CD168 antibody and an HMMR/CD168-HRP conjugate. The assay sample and buffer are incubated together with HMMR/CD168-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the HMMR/CD168 concentration since HMMR/CD168 from samples and HMMR/CD168-HRP conjugate compete for the anti-HMMR/CD168 antibody binding site. Since the number of sites is limited, as more sites are occupied by HMMR/CD168 from the sample, fewer sites are left to bind HMMR/CD168-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The HMMR/CD168 concentration in each sample is interpolated from this standard curve.

217416398

NP_036617.2

NM_012485.2

74,495 Da

Disease Pathway (530764); ECM-receptor Interaction Pathway (83068); ECM-receptor Interaction Pathway (479); Glycogen Storage Diseases Pathway (980468); Glycosaminoglycan Metabolism Pathway (645297); Hyaluronan Metabolism Pathway (645298); Hyaluronan Uptake And Degradation Pathway (645300); MPS I - Hurler Syndrome Pathway (685537); MPS II - Hunter Syndrome Pathway (685538); MPS IIIA - Sanfilippo Syndrome A Pathway (685539)

The protein encoded by this gene is involved in cell motility. It is expressed in breast tissue and together with other proteins, it forms a complex with BRCA1 and BRCA2, thus is potentially associated with higher risk of breast cancer. Alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Dec 2008]

HMMR: Involved in cell motility. When hyaluronan binds to HMMR, the phosphorylation of a number of proteins, including PTK2/FAK1 occurs. May also be involved in cellular transformation and metastasis formation, and in regulating extracellular- regulated kinase (ERK) activity. 4 isoforms of the human protein are produced by alternative splicing. Protein type: Receptor, misc. Chromosomal Location of Human Ortholog: 5q34. Cellular Component: cell surface; membrane; cytoplasm; plasma membrane. Molecular Function: hyaluronic acid binding. Biological Process: glycosaminoglycan metabolic process; carbohydrate metabolic process; pathogenesis; hyaluronan metabolic process; hyaluronan catabolic process. Disease: Breast Cancer

48-Strip-Wells

470 USD

96-Strip-Wells

675